Alopexx

Alopexx is a clinical-stage biotechnology company developing novel broad-spectrum immune-mediated therapies for the prevention and treatment of various bacterial, fungal, and parasitic infections. Alopexx has developed immune therapies capable of targeting a wide range of microbial infections—a chemically synthesized vaccine and a fully human monoclonal antibody. These therapies address a significant unmet medical need—preventing and treating microbial infections without the use of antibiotics. No other immune-mediated anti-infective therapy possesses such broad-spectrum potential.